Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Portfolio Pulse from
The FDA has approved Attruby™ (acoramidis), a near-complete TTR stabilizer, for reducing cardiovascular death and hospitalization in ATTR-CM patients. This is the first product with such a label, showing benefits on cardiovascular outcomes.
November 23, 2024 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BBIO's Attruby™ (acoramidis) has received FDA approval as a near-complete TTR stabilizer for reducing cardiovascular death and hospitalization in ATTR-CM patients. This approval marks a significant milestone for BBIO, potentially boosting its market position and revenue.
The FDA approval of Attruby™ is a significant development for BBIO, as it is the first product with a label specifying near-complete stabilization of TTR. This approval is likely to enhance BBIO's market position and drive revenue growth, leading to a positive short-term impact on its stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100